Your browser doesn't support javascript.
loading
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Collier, Katharine A; Valencia, Hugo; Newton, Herbert; Hade, Erinn M; Sborov, Douglas W; Cavaliere, Robert; Poi, Ming; Phelps, Mitch A; Liva, Sophia G; Coss, Christopher C; Wang, Jiang; Khountham, Soun; Monk, Paul; Shapiro, Charles L; Piekarz, Richard; Hofmeister, Craig C; Welling, D Bradley; Mortazavi, Amir.
Afiliação
  • Collier KA; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Valencia H; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Newton H; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Hade EM; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Sborov DW; Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Cavaliere R; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
  • Poi M; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Phelps MA; Division Neuro-Oncology, Department of Cancer Medicine, Baptist MD Anderson, Jacksonville, FL, USA.
  • Liva SG; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Coss CC; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Wang J; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Khountham S; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Monk P; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Shapiro CL; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Piekarz R; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Hofmeister CC; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.
  • Welling DB; National Cancer Institute/Cancer Therapy Evaluation Program, Bethesda, MD, USA.
  • Mortazavi A; Division of Hematology, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Cancer Chemother Pharmacol ; 87(5): 599-611, 2021 05.
Article em En | MEDLINE | ID: mdl-33492438
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenilbutiratos / Neurofibromatose 2 / Inibidores de Histona Desacetilases / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenilbutiratos / Neurofibromatose 2 / Inibidores de Histona Desacetilases / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Alemanha